<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450787</url>
  </required_header>
  <id_info>
    <org_study_id>000322</org_study_id>
    <nct_id>NCT01450787</nct_id>
  </id_info>
  <brief_title>Prevalence of Dry Eyes in Diabetics Compared to Non Diabetics</brief_title>
  <official_title>Prevalence of Dry Eyes in Diabetics Compared to Non Diabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>COA Research Foundation, INC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>COA Research Foundation, INC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to compare the prevalence of dry eyes in diabetics and non diabetics. This
      might help identify a group of patients at greater risk for dry eye complications. Diabetics
      have been shown to have poor ocular surface healing and might benefit from dry eye therapy
      earlier if they are shown to be at greater risk for dry eyes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dry eye disease is one of the most common eye problems seen in ophthalmology. Diabetics are
      at high risk for multiple eye problems, including retinopathy and glaucoma. They also have
      been shown to have poor ocular surface healing. I would like to evaluate the prevalence of
      dry eye disease in diabetics to see if they are also at greater risk for the known
      complications of dry eye disease. If so, they might benefit from early intervention.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principle investigator changed practice location and discontinued study
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Conjunctival Staining Score</measure>
    <time_frame>at the time of the evaluation</time_frame>
    <description>Conjunctival staining with lissamine green dye is measured at the time of the evaluation on a scale from 0 to 5 using the oxford scoring system, with 5 being the most severe staining.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tear Film Osmolarity</measure>
    <time_frame>at the time of the exam</time_frame>
    <description>The tear film osmolarity is measured at the time of the exam.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>OSDI Score</measure>
    <time_frame>at the time of the exam</time_frame>
    <description>The ocular surface disease index survey in completed at the time of the exam. This scale ranges from 0 to 100 higher scores representing greater disability.</description>
  </other_outcome>
  <other_outcome>
    <measure>Schirmer Score</measure>
    <time_frame>at the time of the exam</time_frame>
    <description>The schirmer tear production test with anesthesia is completed at the time of the exam in mm of tear film absorption on the test strip after five minutes. Higher scores represent greater tear production.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tear Break-up Time</measure>
    <time_frame>at the time of the exam</time_frame>
    <description>The tear break-up time with fluorescein solution is measured at the time of the exam in seconds.</description>
  </other_outcome>
  <other_outcome>
    <measure>Corneal Staining</measure>
    <time_frame>at the time of the exam</time_frame>
    <description>Corneal staining with fluorescein solution is graded at the time of the exam on a scale of 0 to 5 using the oxford scoring system with 5 being the most severe staining.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">63</enrollment>
  <condition>Dry Eyes</condition>
  <arm_group>
    <arm_group_label>diabetics</arm_group_label>
    <description>diabetics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non diabetics</arm_group_label>
    <description>non diabetics</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Existing clinic population from our practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50 patients with diabetes, 25 without diabetes over the age of 40

        Exclusion Criteria:

          -  current use of glaucoma drops or currently within the postoperative period from eye
             surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth A Beckman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>COA Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbus Ophthalmalogy Associates</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2011</study_first_posted>
  <results_first_submitted>March 9, 2013</results_first_submitted>
  <results_first_submitted_qc>August 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2013</results_first_posted>
  <last_update_submitted>August 8, 2013</last_update_submitted>
  <last_update_submitted_qc>August 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dry eyes</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled randomly. Consecutive patients in a private ophthalmology clinic that met inclusion criteria were asked to participate at the time of an already scheduled exam. The non-diabetic group recruitment stopped once the target number of subjects enrolled. The diabetic group recruitment continued until the study was terminated.</recruitment_details>
      <pre_assignment_details>Being that there was no intervention and the study only involved taking measurements at the time of the exam, there was no transition required. Any eligible patient that was willing to participate was included. Consecutive diabetic patients and consecutive non-diabetic patients that met criteria were offered the opportunity to enroll.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Diabetics</title>
          <description>diabetics over age 40</description>
        </group>
        <group group_id="P2">
          <title>Non Diabetics</title>
          <description>non diabetics over age 40</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diabetics</title>
          <description>diabetics over age 40</description>
        </group>
        <group group_id="B2">
          <title>Non Diabetics</title>
          <description>non diabetics over age 40</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Staining Score</title>
        <description>Conjunctival staining with lissamine green dye is measured at the time of the evaluation on a scale from 0 to 5 using the oxford scoring system, with 5 being the most severe staining.</description>
        <time_frame>at the time of the evaluation</time_frame>
        <population>There were 38 consecutive diabetics over 40 years of age and 25 consecutive non-diabetics over 40 years of age that qualified and agreed to enroll. A target of 25 non-diabetics was met. The target of 50 was not met as the study was stopped when the PI changed practices. By that time, 38 diabetics enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Diabetics</title>
            <description>diabetics over age 40</description>
          </group>
          <group group_id="O2">
            <title>Non Diabetics</title>
            <description>non diabetics over age 40</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Staining Score</title>
          <description>Conjunctival staining with lissamine green dye is measured at the time of the evaluation on a scale from 0 to 5 using the oxford scoring system, with 5 being the most severe staining.</description>
          <population>There were 38 consecutive diabetics over 40 years of age and 25 consecutive non-diabetics over 40 years of age that qualified and agreed to enroll. A target of 25 non-diabetics was met. The target of 50 was not met as the study was stopped when the PI changed practices. By that time, 38 diabetics enrolled.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="0.16"/>
                    <measurement group_id="O2" value="2.19" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Film Osmolarity</title>
        <description>The tear film osmolarity is measured at the time of the exam.</description>
        <time_frame>at the time of the exam</time_frame>
        <population>Tear film osmolarity was measured in all patients, but two patients in the diabetic group had an insufficient tear film to obtain a reading. Therefore, only 36 diabetics were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Diabetics</title>
            <description>diabetics over age 40</description>
          </group>
          <group group_id="O2">
            <title>Non Diabetics</title>
            <description>non diabetics over age 40</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Film Osmolarity</title>
          <description>The tear film osmolarity is measured at the time of the exam.</description>
          <population>Tear film osmolarity was measured in all patients, but two patients in the diabetic group had an insufficient tear film to obtain a reading. Therefore, only 36 diabetics were included.</population>
          <units>mOsml/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303.41" spread="2.03"/>
                    <measurement group_id="O2" value="312.06" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>OSDI Score</title>
        <description>The ocular surface disease index survey in completed at the time of the exam. This scale ranges from 0 to 100 higher scores representing greater disability.</description>
        <time_frame>at the time of the exam</time_frame>
        <population>All patients completed the OSDI survey</population>
        <group_list>
          <group group_id="O1">
            <title>Diabetics</title>
            <description>diabetics over age 40</description>
          </group>
          <group group_id="O2">
            <title>Non Diabetics</title>
            <description>non diabetics over age 40</description>
          </group>
        </group_list>
        <measure>
          <title>OSDI Score</title>
          <description>The ocular surface disease index survey in completed at the time of the exam. This scale ranges from 0 to 100 higher scores representing greater disability.</description>
          <population>All patients completed the OSDI survey</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.58" spread="2.62"/>
                    <measurement group_id="O2" value="27.50" spread="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Schirmer Score</title>
        <description>The schirmer tear production test with anesthesia is completed at the time of the exam in mm of tear film absorption on the test strip after five minutes. Higher scores represent greater tear production.</description>
        <time_frame>at the time of the exam</time_frame>
        <population>Each patient underwent schirmer testing</population>
        <group_list>
          <group group_id="O1">
            <title>Diabetics</title>
            <description>diabetics over age 40</description>
          </group>
          <group group_id="O2">
            <title>Non Diabetics</title>
            <description>non diabetics over age 40</description>
          </group>
        </group_list>
        <measure>
          <title>Schirmer Score</title>
          <description>The schirmer tear production test with anesthesia is completed at the time of the exam in mm of tear film absorption on the test strip after five minutes. Higher scores represent greater tear production.</description>
          <population>Each patient underwent schirmer testing</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.36" spread="1.06"/>
                    <measurement group_id="O2" value="15.88" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Tear Break-up Time</title>
        <description>The tear break-up time with fluorescein solution is measured at the time of the exam in seconds.</description>
        <time_frame>at the time of the exam</time_frame>
        <population>Each patient underwent tear break-up time testing</population>
        <group_list>
          <group group_id="O1">
            <title>Diabetics</title>
            <description>diabetics over age 40</description>
          </group>
          <group group_id="O2">
            <title>Non Diabetics</title>
            <description>non diabetics over age 40</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Break-up Time</title>
          <description>The tear break-up time with fluorescein solution is measured at the time of the exam in seconds.</description>
          <population>Each patient underwent tear break-up time testing</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="0.17"/>
                    <measurement group_id="O2" value="3.66" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Corneal Staining</title>
        <description>Corneal staining with fluorescein solution is graded at the time of the exam on a scale of 0 to 5 using the oxford scoring system with 5 being the most severe staining.</description>
        <time_frame>at the time of the exam</time_frame>
        <population>All patients underwent corneal staining evaluations using fluorescein.</population>
        <group_list>
          <group group_id="O1">
            <title>Diabetics</title>
            <description>diabetics over age 40</description>
          </group>
          <group group_id="O2">
            <title>Non Diabetics</title>
            <description>non diabetics over age 40</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Staining</title>
          <description>Corneal staining with fluorescein solution is graded at the time of the exam on a scale of 0 to 5 using the oxford scoring system with 5 being the most severe staining.</description>
          <population>All patients underwent corneal staining evaluations using fluorescein.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.08"/>
                    <measurement group_id="O2" value="0.30" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diabetics</title>
          <description>diabetics over age 40</description>
        </group>
        <group group_id="E2">
          <title>Non Diabetics</title>
          <description>non diabetics over age 40</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kenneth A Beckman, MD</name_or_title>
      <organization>Coa Research Foundation</organization>
      <phone>614-506-4720</phone>
      <email>kenbeckman22@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

